Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,391 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Intimation for receipt of request for reclassification of shareholders category
Regulatory Filings Classification · 80% confidence The document is an SEBI LODR Regulation 30/31A intimation to stock exchanges regarding shareholder reclassification requests (promoter group to public). It is a routine compliance/regulatory announcement rather than a full report, management discussion, earnings release, or major shareholding threshold event. It does not announce actual share issuance, buyback, dividend, or M&A. It is best classified as a general regulatory filing.
2026-05-14 English
General Updates
Regulatory Filings Classification · 86% confidence The document is an exchange intimation under SEBI Listing Regulations about receipt of requests for reclassification of shareholder category (promoter group to public). It is a compliance announcement to stock exchanges and does not itself constitute a financial report, dividend notice, management change, or capital transaction. It falls under general regulatory disclosures and fits the fallback category “Regulatory Filings” (RNS).
2026-05-14 English
Earnings call for the financial results of the fourth quarter on 22 May 2026
Report Publication Announcement Classification · 87% confidence The document is a press release announcing the timing of the company’s fourth quarter results release and the related earnings call, but it does not contain any actual financial data or results. It merely informs investors when the earnings release will be published and when the conference call will take place. This fits the definition of a Report Publication Announcement (RPA) rather than an actual earnings release or interim report.
2026-05-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Report Publication Announcement Classification · 91% confidence The document is a press release dated 13 May 2026 from Sun Pharma announcing the date and logistics for the Q4 FY2026 earnings call and the forthcoming publication of the financial results on 22 May 2026. It does not contain any actual financial data or results, nor is it the report itself or a transcript. It simply informs stakeholders when and where the report (earnings release) and call will occur and how to access it. This matches the definition of a Report Publication Announcement (RPA).
2026-05-13 English
Change in Director(s)
Board/Management Information Classification · 98% confidence The document is a formal regulatory announcement under SEBI Listing Regulations detailing the appointment of an Independent Director and changes in committee composition. It does not contain financial statements, earnings data, or proxy materials – it purely concerns board and committee membership changes. This fits the category for announcements of changes in the company’s board of directors or senior management.
2026-05-12 English
Change in Board of Directors and Composition of Committees
Board/Management Information Classification · 92% confidence The document is a formal stock exchange announcement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying the appointment of an Independent Director and changes in the composition of board committees. It clearly relates to board-level management changes rather than financial reporting, voting results, or other categories. Therefore, it falls under Board/Management Information (MANG).
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.